CN113166150B - 经取代的黄嘌呤衍生物 - Google Patents
经取代的黄嘌呤衍生物 Download PDFInfo
- Publication number
- CN113166150B CN113166150B CN201980081691.3A CN201980081691A CN113166150B CN 113166150 B CN113166150 B CN 113166150B CN 201980081691 A CN201980081691 A CN 201980081691A CN 113166150 B CN113166150 B CN 113166150B
- Authority
- CN
- China
- Prior art keywords
- disorder
- trpc5
- mixture
- mmol
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212059 | 2018-12-12 | ||
| EP18212059.2 | 2018-12-12 | ||
| PCT/EP2019/084373 WO2020120449A1 (en) | 2018-12-12 | 2019-12-10 | Substituted xanthine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113166150A CN113166150A (zh) | 2021-07-23 |
| CN113166150B true CN113166150B (zh) | 2023-12-01 |
Family
ID=64665183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980081691.3A Active CN113166150B (zh) | 2018-12-12 | 2019-12-10 | 经取代的黄嘌呤衍生物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12291532B2 (https=) |
| EP (1) | EP3894409B1 (https=) |
| JP (1) | JP7408662B2 (https=) |
| CN (1) | CN113166150B (https=) |
| WO (1) | WO2020120449A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3894409B1 (en) * | 2018-12-12 | 2023-08-23 | Boehringer Ingelheim International GmbH | Substituted xanthine derivatives |
| KR20250141831A (ko) * | 2023-02-08 | 2025-09-29 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 잔틴계 화합물 및 이의 용도 |
| WO2024236027A1 (en) * | 2023-05-18 | 2024-11-21 | Boehringer Ingelheim International Gmbh | 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione for use in the treatment of borderline personality disorder |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105143229A (zh) * | 2013-03-15 | 2015-12-09 | 海德拉生物科学有限公司 | 取代的黄嘌呤及其使用方法 |
| WO2019011802A1 (en) * | 2017-07-11 | 2019-01-17 | Boehringer Ingelheim International Gmbh | NEW SUBSTITUTED XANTHINE DERIVATIVES |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6667093B2 (ja) | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体 |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| EP3894409B1 (en) * | 2018-12-12 | 2023-08-23 | Boehringer Ingelheim International GmbH | Substituted xanthine derivatives |
-
2019
- 2019-12-10 EP EP19820717.7A patent/EP3894409B1/en active Active
- 2019-12-10 CN CN201980081691.3A patent/CN113166150B/zh active Active
- 2019-12-10 US US17/312,831 patent/US12291532B2/en active Active
- 2019-12-10 JP JP2021533341A patent/JP7408662B2/ja active Active
- 2019-12-10 WO PCT/EP2019/084373 patent/WO2020120449A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105143229A (zh) * | 2013-03-15 | 2015-12-09 | 海德拉生物科学有限公司 | 取代的黄嘌呤及其使用方法 |
| WO2019011802A1 (en) * | 2017-07-11 | 2019-01-17 | Boehringer Ingelheim International Gmbh | NEW SUBSTITUTED XANTHINE DERIVATIVES |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113166150A (zh) | 2021-07-23 |
| JP7408662B2 (ja) | 2024-01-05 |
| EP3894409A1 (en) | 2021-10-20 |
| US20220056032A1 (en) | 2022-02-24 |
| EP3894409B1 (en) | 2023-08-23 |
| JP2022512374A (ja) | 2022-02-03 |
| WO2020120449A1 (en) | 2020-06-18 |
| US12291532B2 (en) | 2025-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5581318B2 (ja) | 神経変性疾患治療用のｇｓｋ３−ベータ阻害剤としての４−（ピリジン−４−イル）−１ｈ−（１，３，５）トリアジン−２−オン誘導体 | |
| CN113166150B (zh) | 经取代的黄嘌呤衍生物 | |
| JP7114702B2 (ja) | 新規置換キサンチン誘導体 | |
| WO2023041055A1 (zh) | Kif18a抑制剂 | |
| KR101905295B1 (ko) | 나프티리딘디온 유도체 | |
| TWI825243B (zh) | 新穎之經取代黃嘌呤衍生物 | |
| JP6526064B2 (ja) | ピリドピリミジンジオン誘導体 | |
| WO2014152135A1 (en) | Polymorphs and salts of a compound | |
| TW202523331A (zh) | 作為sstr4激動劑之(2s,5r)-5-(羥甲基)嗎啉-2-甲醯胺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |